Natural Biogenex, a subsidiary of Natural Capsules Limited, has signed definitive Framework and Contract Manufacturing Agreements with Fermbox Bio to advance fermentation-based Contract Development and Manufacturing Organization (CDMO) services.

 

Under the deal, Fermbox Bio will supply advanced fermentation technology and equipment worth up to ₹60 crore at NBPL’s cutting-edge facility in Tumkur. NBPL will handle licensed manufacturing, quality assurance, and regulatory compliance, creating a fully integrated, GMP-compliant platform capable of serving global biotechnology and biopharma clients with enhanced process efficiency.

 

The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand, increasing outsourcing, and increasingly complex biomanufacturing needs. India, with its growing CDMO sector, is well-positioned to capture a significant slice of this opportunity.

 

Government initiatives like the BioE3 Policy and the RDI program are further accelerating innovation and scaling capabilities, strengthening India’s broader biomanufacturing ecosystem.

 

“This partnership marks a pivotal step for Natural Biogenex and, by extension, for Natural Capsules Group, in expanding into high-value, fermentation-based bio-manufacturing CDMO service for pharma and allied products. 

 

"The collaboration with Fermbox combines our licensed manufacturing strength and regulatory excellence with their advanced technology, enabling value-accretive, scalable growth in both pharmaceutical and industrial biotech segments,” said Managing Director Sunil Laxminarayana Mundra.